Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Clear Secure Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Clear Secure Inc trades at $44.26 (market cap $4.49B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Clear Secure Inc pays a 1.32% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Clear Secure Inc for 20 Days on average.
| SYRE | YOU | |
|---|---|---|
Market Cap | $7.52B | $4.49B |
Volume | 1,441,031 | 1,674,277 |
Sector | Health | Technology |
52-Week High | $108.92 | $62.36 |
52-Week Low | $22.18 | $30.47 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $6.52B | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Clear Secure (YOU) trades at $43.52, up 2.5% over the past day, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong Q2 2026 results with EPS of $0.49 beating estimates, revenue growth of 27% year-over-year, and robust profitability metrics including a 66.66% gross margin. Recent developments include a strategic partnership with CrowdStrike and the launch of corporate memberships.
The outlook is positive given accelerating membership growth and expanding margins, though risks include competitive pressures and reliance on airport services. Analysts are generally bullish with a consensus price target of $61.40, representing significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
